Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges
The DOI matches its Crossref record; 176 of the 177 references it cites were found in a registry or an index.
Abstract
In vivo gene replacement for the treatment of inherited disease is one of the most compelling concepts in modern medicine. Adeno-associated virus (AAV) vectors have been extensively used for this purpose and have shown therapeutic efficacy in a range of animal models. Successful translation to the clinic was initially slow, but long-term expression of donated genes at therapeutic levels has now been achieved in patients with inherited retinal disorders and haemophilia B. Recent exciting results have raised hopes for the treatment of many other diseases. As we discuss here, the prospects and challenges for AAV gene therapy are to a large extent dependent on the target tissue and the specific disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This immune cascade model might explain why re-administration in patients could become difficult, and why the administration of rAAVs in patients with high neutralizing antibodies (nAbs) are generally not included in clinical trials [327].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [327]
Citations
Cites
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 1×
“The disease is currently treated by intravenous infusion of clotting factor concentrate”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Research works printed but not linked: 3
- Basner-Tschakarjan, E. et al. Dose-dependent activation of capsid-specific T cells after AAV serotype 8 vector administration in a clinical study for hemophilia. Mol. Ther. (in the press).
- Mingozzi, F. et al. Modulation of T cell response to the AAV capsid in subjects undergoing intramuscular gene transfer for lipoprotein lipase deficiency. Hum. Gene Ther. 19, 1090 (2008).
- Muzyczka, N. & Berns, K. I. in Parvoviridae: The Viruses and their Replication (eds Knipe, D. M. & Howley, P. M.) 2437–2477 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
Cited by
Items 701–800 of 892
Recombinant DNA technology and gene therapy
Sivamani, Y., Hegde, S., Bhat, A. R., Sajal, H., & Elayaperumal, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-16013-4.00017-8 · Cited by 4
Erbasan, E., Aliciaslan, M., Erendor, F., Şanlioğlu, A. D., & Şanlıoğlu, S. (2025) · Gene Therapy · doi:10.1038/s41434-025-00575-0 · Cited by 8
Tavakolidakhrabadi, N., Ding, W. Y., Welsh, G. I., & Saleem, M. A. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf332 · Cited by 4
“Therefore, ensuring durable and stable transgene expression is essential for long-term efficacy [185 ].”
Navigating molecular therapies: The emerging role of mRNA in treating inherited metabolic diseases
Castro-Alpízar, J., Lenderink, M. J., Nieuwenhuis, E. E. S., Kooijmans, S. A. A., & Fuchs, S. A. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109698 · Cited by 5
Sun, H., Teng, Q., Liu, W., Guo, R., Li, M.-H., Xiong, W., Huang, Q., Yu, Q., Luo, N., Li, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67112-w · Cited by 5
RNA‐binding motif protein 24 inhibits HBV replication in vivo
Yao, Y., Chen, Y., Huang, D. F., Liu, C., Sun, H., Zhou, Y., Pei, R., Wang, Y., Wen, Z., Yang, B., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28969 · Cited by 4
“AAV8 vectors are the most suitable gene delivery platform for transferring hepatic genes.(26) In this study, the recombinant AAV8‐ RBM24 vector and the loss‐of‐function AAV8‐RBM24ΔRNP1/2 control vector were constructed and injected into C57BL/6J mice for determining the potential distribution of AAV‐RBM24 in healthy m…”
MethodSong, Z., Liu, P., Zhang, D., Wang, T., Yue, W., Geng, Y., Liu, N., Wang, Y., & Yang, J. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01036-4 · Cited by 5
Yang, X., Ren, Y., Li, X., Liang, X., & Wan, J. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70163 · Cited by 4
“Recognized for its efficacy in gene transfer [28], AAV has shown exceptional capability for genetic interventions in pancreatic tissue [20].”
Rudd, P. A., & Herrero, L. J. (2018) · InTech eBooks · doi:10.5772/intechopen.71071 · Cited by 4
Luo, M., Huang, H., Hou, L., Shao, S. H., Huang, S., & Zhao, X. (2017) · Oncology Letters · doi:10.3892/ol.2017.5601 · Cited by 4
Pushing the Right Buttons: Improving Efficacy of Therapeutic DNA Vectors
Hacobian, A., & Hercher, D. (2017) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2017.0353 · Cited by 6
“In order to introduce exogenous DNA into cells in vitro and in vivo, several strategies based on viral or non-viral approaches are available.(2,3) Viral gene transfer strategies (retroviruses,(4) adenoviruses,(5) adeno-associated viruses,(6,7) herpes viruses,(8) lentiviruses(9) and Epstein-Barr viruses(10)) show by fa…”
Levy, H. C., Hulvey, D., Adamson-Small, L. A., Jn‐Simon, N., Prima, V., Rivkees, S. A., & Hobbs, J. A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228005 · Cited by 4
La respuesta a proteínas mal plegadas como blanco terapéutico en la enfermedad de Alzheimer
Rivera-Krstulović, C., & Duran-Aniotz, C. A. (2020) · Revista médica de Chile · doi:10.4067/s0034-98872020000200216 · Cited by 7
Gene therapy in a murine model of chronic eosinophilic leukemia-not otherwise specified (CEL-NOS)
Pagovich, O. E., Stiles, K. M., Camilleri, A. E., Russo, A. R., Nag, S., & Crystal, R. G. (2021) · Leukemia · doi:10.1038/s41375-021-01400-4 · Cited by 4
Dhote, V. V., Samundre, P., Upaganlawar, A., & Ganeshpurkar, A. (2021) · Current Gene Therapy · doi:10.2174/1566523221666211123101441 · Cited by 5
CRISPR/Cas9: A Molecular Tool for Ovarian Cancer Management beyond Gene Editing
Dholariya, S. J., Parchwani, D. N., Radadiya, M., Singh, R., Sonagra, A. D., Patel, D. D., & Sharma, G. (2022) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2022043814 · Cited by 4
Genetic Medicine for Hearing Loss: OTOF as Exemplar
Hickox, A. E., Valero, M. D., McLaughlin, J. T., Robinson, G. S., Wellman, J. A., McKenna, M. J., Sewell, W. F., & Simons, E. J. (2021) · Journal of the American Academy of Audiology · doi:10.1055/s-0041-1730410 · Cited by 4
Emmerling, V. V., Holzmann, K., Lanz, K., Kochanek, S., & Hörer, M. (2013) · BMC Proceedings · doi:10.1186/1753-6561-7-s6-p12 · Cited by 5
Hitching a Ride: Enhancing Nucleic Acid Delivery into Target Cells Through Nanoparticles
Penumarthi, A., Basak, P., Smooker, P. M., & Shukla, R. (2020) · Environmental chemistry for a sustainable world · doi:10.1007/978-3-030-29207-2_11 · Cited by 6
Sharma, A., Mathew, M. E., Sriganesh, V., Neely, J. A., & Kalipatnapu, S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010822.pub2 · Cited by 4
Cell and gene therapeutic approaches in non-alcoholic fatty liver disease
Poudineh, M., Mohammadyari, F., Parsamanesh, N., Jamialahmadi, T., Kesharwani, P., & Sahebkar, A. (2025) · Gene · doi:10.1016/j.gene.2025.149466 · Cited by 3
Current and Emerging Therapeutic Strategies for the Treatment of Duchenne Muscular Dystrophy
Perez, M. L., & Weisleder, N. L. (2026) · Genes · doi:10.3390/genes17050533 · Cited by 3
“AAV vectors are non-integrating, muscle-tropic delivery systems that have historically been viewed as having a comparatively favorable translational profile for in vivo muscle gene delivery, thus they have become the platform of choice for systemic gene delivery in DMD [63].”
Bax, B. D., Sutormin, D. A., McDonald, N. Q., Burley, G. A., & Shelkovnikova, T. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911541 · Cited by 3
“Lentiviruses, adenoviruses and AAVs were tested as delivery vectors, with AAVs being most popular in gene therapy clinical trials due to a number of favorable characteristics [76].”
MethodHuang, W., Mohammed, T., Zou, X., Krishnan, A. A., Mo, X. M., Xiao, M., & Cao, L. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101500 · Cited by 4
Gene Therapy for Type 1 Diabetes Moves a Step Closer to Reality
O’Brien, T. (2013) · Diabetes · doi:10.2337/db13-0348 · Cited by 3
“The use of AAV is certainly appropriate given the safety profile and the ability to obtain long-term gene expression (7).”
BackgroundGene Therapy: Use of Viruses as Vectors
Nance, M. E., & Duan, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95711-8 · Cited by 3
Zubkova, E., Beloglazova, I. B., Evtushenko, E. G., Kopylov, A. T., Шевченко, Е. К., Дергилев, К. В., Ratner, E. I., Парфенова, Е. В., & Menshikov, M. Y. (2019) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-019-04387-2 · Cited by 3
Toward the quantification of adeno-associated virus titer by electrochemical impedance spectroscopy
Wang, J., Hosseini, M., Shastry, S., Barbieri, E., Chu, W., Menegatti, S., & Daniele, M. A.-A. (2023) · IEEE BioSensors Conference (BioSensors) · doi:10.1109/biosensors58001.2023.10281105 · Cited by 4
“AAV vectors have been shown in various studies to be an effective long-term in vivo gene transfer tool for therapeutics, vaccines, and for use with CRISPR and CAR-T therapies [5].”
BackgroundTherapeutic Gene Editing in Muscles and Muscle Stem Cells
Tabebordbar, M., Cheng, J. K. W., & Wagers, A. J. (2017) · Research and perspectives in neurosciences · doi:10.1007/978-3-319-60192-2_10 · Cited by 3
“While pre-existing and acquired immunity to AAV remains a challenge for systemic, and repeated, administration of AAV vectors in human populations, these issues have been investigated for several decades and promising pharmacologic and physical strategies have emerged (Mingozzi and High 2011).”
BackgroundInfluentialVers une thérapie génique de certaines surdités congénitales ?
Hardelin, J., & Safieddine, S. (2019) · médecine/sciences · doi:10.1051/medsci/2019233 · Cited by 4
Silencing of BCSG1 with specific siRNA via nanocarriers for breast cancer treatment
Yang, C., Cheng, X., & Shen, P. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.10.022 · Cited by 3
High-Level rAAV Vector Production by rAdV-Mediated Amplification of Small Amounts of Input Vector
Weger, S. (2022) · Viruses · doi:10.3390/v15010064 · Cited by 3
“These properties have boosted the use of rAAV in gene transfer protocols for the treatment of a variety of genetic diseases such as hemophilia [1,2], metabolic disorders [3], congenital blindness [4,5] and muscular dystrophies [6], also highlighted by the recent clinical approvals of the AAV serotype 2 based vector Lu…”
BackgroundZhou, K., Yuan, M., Sun, J., Zhang, F., Zong, X., Li, Z., Tang, D., Zhou, L., Zheng, J., Xiao, X., et al. (2023) · Gene Therapy · doi:10.1038/s41434-023-00411-3 · Cited by 3
Artificial Intelligence-Mediated Computer-Aided Design of Viral Gene Therapies
Daneshvar, A., & Lukianov, S. N. (2023) · GEN Biotechnology · doi:10.1089/genbio.2023.0014 · Cited by 3
“86,87”
Recent developments in gene therapy research in India
Selot, R., & Ghosh, A. (2024) · Journal of Biosciences · doi:10.1007/s12038-024-00423-0 · Cited by 7
“AAV vectors have gained prominence in gene therapy due to high expression with different transgenes (Asokan et al. 2010; Mingozzi and High 2011a, 2011b disorders, such as hemophilia, muscular dystrophy, and a 1-anti-trypsin deficiency (Zincarelli et al. 2008; Nathwani et al. 2017; Duan et al. 2021).”
Velho, R. V., Sperb‐Ludwig, F., & Schwartz, I. V. D. (2015) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201520140711 · Cited by 4
RANGE: Gene Transfer of Reversibly Controlled Polycistronic Genes
Chen, Y., Cao, L., Luo, C., Ditzel, D. A. W., Peter, J., & Sprengel, R. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.15 · Cited by 3
Natural polymers in nucleic acid delivery
Aliabadi, H. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-08-100520-0.00003-5 · Cited by 4
Mitochondria-Targeted Antiaging Gene Therapy with Adeno-associated Viral Vectors
Li, D., & Duan, D. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-556-9_13 · Cited by 3
“Of available gene transfer vehicles, adeno-associated virus (AAV) stands out as an extremely safe and effective vector for local or whole-body gene transfer [15].”
BackgroundOptogénétique et douleur chronique : une stratégie applicable chez l’humain ?
Beaudry, H., Daou, I., Ribeiro‐da‐Silva, A., & Séguéla, P. (2016) · Douleur et Analgésie · doi:10.1007/s11724-016-0477-9 · Cited by 3
Trends in orally viral vector gene delivery and therapy
Xie, J., & Xu, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-47720-8.00006-7 · Cited by 6
Nemirovich-Danchenko, N. M., & Khodanovich, M. Y. (2020) · Russian Journal of Genetics · doi:10.1134/s1022795420040092 · Cited by 3
“For example, the AAV2/9 serotype, which effectively infects neurons and astrocytes in the brain, also infects a wide range of cells in various organs [152].”
Hypothalamic gene transfer of BDNF promotes healthy aging
Cao, L., Ali, S., & Queen, N. J. (2021) · Vitamins and hormones · doi:10.1016/bs.vh.2020.12.003 · Cited by 4
Challenges Posed by Gene Manipulations and Sport Performance
Cohen‐Haguenauer, O. (2021) · Springer eBooks · doi:10.1007/978-3-030-79293-0_4 · Cited by 3
Wang, Z., Fu, Q., Cao, J., Deng, X., Li, Y., Wang, Q., & Zheng, Z. (2016) · Biotechnology Letters · doi:10.1007/s10529-016-2082-7 · Cited by 3
How does “Protein Corona” Affect the In vivo Efficiency of Polymeric Nanoparticles? State of Art
(2017) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781681084930117020011 · Cited by 6
Haurigot, V., Jiménez, V., & Bosch, F. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch70 · Cited by 3
Zhu, X., Yang, K., Xie, J., Feng, X.-L., Wu, T., Hu, M., Wang, H., Yu, C., Yu, X., Hemmatzadeh, F., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0315921 · Cited by 3
Qie, B., Li, J., Wan, M., & Zhu, Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126298 · Cited by 2
Zhang, F., Dong, C., Chow, R. D.-W., Xin, S., He, E., Feng, Y., Zhu, L., Mirza, D., Tian, X., Yang, L., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0545 · Cited by 5
Lin, T.-M., Chang, H., Lin, T.-C., Lin, C.-S., Sun, Y., & Lin, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70800 · Cited by 2
Ahmadiankia, N., Neshati, V., Neshati, Z., Swildens, J., & de Vries, A. A. F. (2013) · PubMed Central · Cited by 2
Heinrich, C., & Rouaux, C. (2015) · médecine/sciences · doi:10.1051/medsci/20153101011 · Cited by 2
Nanoparticle-mediated therapy of neuronal damage in the neonatal brain
Zhou, W. P., Fu, Y., Zhang, M., Buabeid, M. A., Ijaz, M., & Murtaza, G. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102208 · Cited by 3
Enhanced Transduction of P2X7-Expressing Cells with Recombinant rAAV Vectors
Mann, A. M., Schäfer, W., Adriouch, S., Börner, K., Grimm, D., Braren, I., & Koch‐Nolte, F. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2384-8_7 · Cited by 2
Holtkamp, S., Lagoda, F. R., Lister, A., Harish, P., Kleymann, U., Pesch, T., Soon, C. F., Pirmohamed, M., Naisbitt, D. J., & Trautwein, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1450524 · Cited by 3
Woo, H., LEE, W. I., Kim, J. H., Ahn, J., Han, J. H., Lim, S. Y., Lee, W. W., & Lee, H. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3194 · Cited by 2
Ma, X., Zhao, A., YAO, Y., Cao, W., Karmacharya, U., Liu, F., Chen, B., BAOZHU, W., Ying, H., & Ma, Y. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3147 · Cited by 2
“Adeno-associated virus (AAV) has previously been used as a gene therapy vector due to its low immunogenicity and sustained transgene expression (5).”
Lange, W., Jin, L., Maybeck, V., Meisenberg, A., Baumann, A., & Offenhäusser, A. (2014) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2038437 · Cited by 3
Gene Delivery to Neurons of the Dorsal Root Ganglia Using Adeno-Associated Viral Vectors
Fagoe, N. D., Eggers, R., Verhaagen, J., & Mason, M. R. J. (2015) · Neuromethods · doi:10.1007/978-1-4939-2306-9_7 · Cited by 2
Gene Therapy in Monogenic Congenital Myopathies
Guan, X., Goddard, M. A., Mack, D. L., & Childers, M. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800548-4.00013-9 · Cited by 2
Mitochondrially targeted zinc finger nucleases
Silva-Pinheiro, P., Gammage, P. A., & Minczuk, M. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819656-4.00019-x · Cited by 3
Gene Editing and Gene Therapies in Cancer Treatment
Tripathi, G., Faiyaz, M., Hasan, Z., Khanam, A., & Husain, A. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-6530-8.ch005 · Cited by 2
Moreno-Gutiérrez, D. S., Zepeda–Cervantes, J., Vaca, L. A., & Hernández-García, A. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112348 · Cited by 3
Grosios, K., Petry, H., & Lubelski, J. (2014) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-94-017-9214-1_9 · Cited by 2
“One type of vector that has long been considered to be the most suitable and safe vector for long-term transgene expression is AAV [ 12 – 14 ].”
BackgroundSeeing Engineered Loops in a Gene Delivery Vehicle by cryoEM
Zhou, Z. (2012) · Structure · doi:10.1016/j.str.2012.07.008 · Cited by 2
“Engineered AAV variants have been optimized as potential gene delivery vehicles, thanks to their non-inflammatory and nonpathogenic properties, wide cell tropism and ease of large scale production (Mingozzi and High, 2011).”
BackgroundNanoparticles for DNA delivery
Mahato, M., Sharma, A. K., & Kumar, P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-100557-6.00004-3 · Cited by 3
Recent advances in cardiac gene therapy strategies targeting advanced heart failure
Chen, C., Seeger, T., Termglinchan, V., & Karakikes, I. (2017) · Continuing Cardiology Education · doi:10.1002/cce2.68 · Cited by 3
“7 kb), which constrains the size of the transgene expression cassette that can be used [10].”
BackgroundUnderperforming Big Ideas in Biomedical Research
Miller, D. G., & Sittig, D. F. (2017) · JAMA · doi:10.1001/jama.2016.19997 · Cited by 2
Breaking the Barriers of Genetic and Metabolic Disorders
Büning, H., Bosch, F., & Mingozzi, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.29093.hbu · Cited by 2
Self-citationZhang, W., Solanki, M., Müther, N., Ebel, M., Wang, J., Sun, C., Izsvák, Z., & Ehrhardt, A. (2013) · PLoS ONE · doi:10.1371/annotation/058e5bbd-d902-4936-b763-a5a3c5cc995e · Cited by 2
Batts, A. J., Ji, R., Bae, S., Tsitsos, F. N., Jiménez-Gambín, S., Kwon, N., Gorman, S. L., Tsakri, D., Noel, R. L., Bendig, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.02.639893 · Cited by 3
Gene Therapy for Neurological Disorders: Molecular Approaches for Targeted Treatment
Malviya, R., Singh, A. K., Goyal, P., & Sundram, S. (2024) · Apple Academic Press eBooks · doi:10.1201/9781003494102 · Cited by 1
Gene therapy in neurodegenerative disorders
Ali, H. T., Sula, I., Elrefaey, A., Ashour, Y., Eltaras, M. M., Mohamed, H., & Meshref, M. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00036-1 · Cited by 1
Mushrooms Lichens and Allopathic Medicine Principles and Performs
Akram, M., Elkhateeb, W. A., & Somasekhar, T. (2025) · Journal of Biomedical Research & Environmental Sciences · doi:10.37871/jbres2051 · Cited by 1
“Muscular dystrophy and cystic fi brosis are the most commonly known genetic conditions that hold promise for gene treatment, which is a kind of treatment that alters a patient's DNA to either prevent or treat a disease [25].”
Recombinant AAV gene transfer: Emerging applications in immune modulation and cancer therapy
Yang, Y., Chen, R., Bao, Y., Han, H., Ma, K., Pei, X., Zhang, L., & Shao, W. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117332 · Cited by 2
Promises and potential pitfalls of in vivo CAR gene therapy
Wagner, D. L., Elsallab, M., & Maus, M. V. (2026) · Blood · doi:10.1182/blood.2025031898 · Cited by 2
Atanassov, V., & Vazharova, R. (2011) · Biotechnology & Biotechnological Equipment · doi:10.5504/bbeq.2011.0104 · Cited by 1
Ophthalmology: potential future developments in China and worldwide
Jonas, J. B., Panda‐Jonas, S., Yaxing, W., & Wenbin, W. (2014) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20140241 · Cited by 1
Gene Therapy of CNS Disorders Using Recombinant AAV Vectors
Murlidharan, G., Samulski, R. J., & Asokan, A. (2016) · Springer eBooks · doi:10.1007/978-1-4899-7654-3_2 · Cited by 1
Carlon, M. S., Vidović, D., Dooley, J., da Cunha, M. G. M. C. M., Maris, M., Lampi, Y., Toelen, J., den Haute, C. V., Baekelandt, V., Deprest, J. A., et al. (2013) · Human Gene Therapy · Cited by 2
Gene- and Cell-Based Therapy for Cardiovascular Disease
Marín-García, J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404599-6.00023-8 · Cited by 3
Immune System Obstacles to In vivo Gene Transfer with Adeno-Associated Virus Vectors
Büning, H., & Mingozzi, F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00004-x · Cited by 1
Self-citationTreating Genetic Disorders Using State-Of-The-Art Technology
Jamal, M., Ullah, A., Ahsan, M., Tyagi, R., Habib, Z., Khan, F. A., & Rehman, K. (2017) · Current Issues in Molecular Biology · doi:10.21775/cimb.026.033 · Cited by 1
Wang, P. L., Lei, X. Q., Xu, T. S., Shi, M. Y., Song, Z., Li, Z. H., Wei, G. H., Zhang, G., & Li, J. T. (2017) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162017050156 · Cited by 1
Gene therapy strategies for X-linked myotubular myopathy
Pierson, C. R. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1443807 · Cited by 1
“gene therapy still poses risks, which, despite the favorable properties of AAV, still include some potential risk for tumorigenicity and untoward immune responses [54].”
BackgroundPrecise Medicine of Restrictive Cardiomyopathy
Wu, Q., Cheang, I., & Li, X. (2018) · Journal of Cardiology and Therapy · doi:10.17554/j.issn.2309-6861.2018.05.147 · Cited by 1
“The gene therapy using adeno-associated virus (AAV) to transform through virus engineering as a carrier has been recognized[31].”
MethodTerapias avanzadas en enfermedades raras
Fillat, C., Río, M. D., Martínez‐Santamaría, L., & Bueren, J. A. (2018) · Arbor · doi:10.3989/arbor.2018.789n3009 · Cited by 1
AAV-Mediated Exon Skipping for Duchenne Muscular Dystrophy
Benchaouir, R., & Goyenvalle, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_20 · Cited by 1
THE JEREMIAH METZGER LECTURE NOVEL THERAPEUTIC STRATEGIES OF ALLERGIC AND IMMUNOLOGIC DISORDERS.
Crystal, R. G., & Pagovich, O. E. (2018) · Europe PMC (PubMed Central) · Cited by 1
Shah, E., Kadam, A. A., Jubin, T., Begum, R., Upadhyay, P., & Soni, H. P. (2019) · ChemistrySelect · doi:10.1002/slct.201900964 · Cited by 1
Geroscience and Management of Osteoporosis in Older Adults
Miedany, Y. M. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-87950-1_19 · Cited by 1
Worgall, S., & Crystal, R. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00029-0 · Cited by 3
Wang, K., Zheng, M., Askew, C., Zhang, X., Li, C., & Han, Z. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200128 · Cited by 3
Viral‐Mediated Delivery of shRNA and miRNA
Manfredsson, F. P. (2013) · Wiley eBooks · doi:10.1002/9781118610749.ch11 · Cited by 2
Adeno-Associated Virus Vectors for Gene Therapy
Mietzsch, M. (2014) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-10246 · Cited by 1
Sharma, A., Mathew, M. E., Neely, J. A., Kalipatnapu, S., & Sriganesh, V. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010822 · Cited by 1
Functional modification of polymeric nanogels
Kusmus, D. N. M. (2021) · doi:10.3990/1.9789036552837 · Cited by 2
A step by step protocol for genomic knock-in of long sequences using dCas9-SSAP editorPreprint
Wang, C., Qu, Y., Cheng, J. K. W., Hughes, N. W., Zhang, Q., Wang, M., & Cong, L. (2022) · Research Square · doi:10.21203/rs.3.pex-1711/v1 · Cited by 1
The DARPin Encyclopedia: from Basic Research towards TherapeuticsPreprint
Wild, P. S., Eapen, R., Forrer, P., & Jost, C. (2022) · Preprints.org · doi:10.20944/preprints202206.0147.v3 · Cited by 2
Metadata
- Authors
- Mingozzi, F., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- High, Katherine A.
- Venue
- Nature Reviews Genetics
- Published
- 2011-04-18
- Volume
- 12
- Issue
- 5
- Pages
- 341-355
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2012894204
- Cited by
- 893
- References
- 177
- Citations by year
- 2026: 13 · 2025: 30 · 2024: 51 · 2023: 39 · 2022: 43 · 2021: 53 · 2020: 66 · 2019: 62 · 2018: 66 · 2017: 80 · 2016: 70 · 2015: 82 · 2014: 74 · 2013: 73 · 2012: 65
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Update notices
- erratum (2011-05-24)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Heart, Lung, and Blood Institute (P01HL064190, HL64190, HL078810, P01HL078810)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- adeno-associated virus vectors, gene therapy, in vivo gene delivery, genetic disorders, gene replacement, inherited retinal disease, hemophilia B
- MeSH terms
- Dependovirus, Animals, Hemophilia B, Clinical Trials as Topic, Dogs, Genetic Vectors, Humans, Male, Retinal Diseases, Genetic Therapy, Gene Transfer Techniques, Genetic Diseases, Inborn, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.